BridgeBio Pharma (BBIO) Convertible Debt (2020 - 2025)

BridgeBio Pharma (BBIO) has 6 years of Convertible Debt data on file, last reported at $739.9 million in Q2 2025.

• For the quarter ending Q2 2025, Convertible Debt rose 35.94% year-over-year to $739.9 million; the trailing twelve-month figure through Jun 2025 stood at $739.9 million (up 35.94% YoY), and the FY2024 full-year result was $738.9 million, up 35.98% from the prior year.
• Convertible Debt rose to $739.9 million in Q2 2025, from $545.6 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $739.9 million in Q2 2025 to a low of $539.5 million in Q3 2021.
• A 5-year average of $628.3 million and a median of $545.2 million in 2024 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt jumped 98.35% in 2021 and slipped 26.14% in 2022, its largest moves.
• Tracing BBIO's Convertible Debt over 5 years: stood at $733.1 million in 2021, then declined by 26.12% to $541.6 million in 2022, then gained by 0.32% to $543.4 million in 2023, then soared by 35.98% to $738.9 million in 2024, then gained by 0.14% to $739.9 million in 2025.
• Business Quant data shows BBIO's Convertible Debt at $739.9 million in Q2 2025, $545.6 million in Q1 2025, and $738.9 million in Q4 2024.